Abstract

TP63 (p63), a member of the tumor suppressor TP53 (p53) gene family, is essential for ectodermal tissue development and suppresses malignant progression of carcinomas. The most abundant isoform, \( \Delta Np63 \alpha \) (referred to as \( \text{p}63 \)), lacks the N-terminal transactivation (TA) domain, and was originally characterized as a dominant-negative type suppressor against p53 family proteins. It also binds to TCF/LEF to inhibit \( \beta \)-catenin. Nevertheless, transcriptional activation by p63 has also been observed in varied systems. To understand the puzzling results, we analyzed the structure–function relationship of p63 in the control of \( \beta \)-catenin-dependent transcription. p63 acted as a suppressor of moderately induced \( \beta \)-catenin. However, when nuclear targeted S33Y \( \beta \)-catenin was applied to cause the maximum enhancer activation, p63 displayed a \( \beta \)-catenin-coactivating function. The DNA-binding domain of p63 and the target sequence facilitated it. Importantly, we newly found that, despite the absence of TA domain, p63 was associated with p300, a general adaptor protein and chromatin modifier causing transcriptional activation. C-terminal \( \alpha \) domain of p63 was essential for p300-binding and for the coactivator function. These results were related to endogenous p63-p300 complex formation and Wnt/\( \beta \)-catenin-responsive gene regulation by p63 in squamous cell carcinoma lines. The novel p63-p300 interaction may be involved in positive regulation of gene expression in tissue development and carcinogenesis.

Introduction

\( \text{p}63 \) (TP63), a member of the tumor suppressor p53 (TP53) gene family [1–3], is essential for ectodermal tissue development and controls carcinogenesis and malignant progression [4–6]. This gene encodes transcriptional activation domain-containing isoforms (TA-p63) that resemble p53 and N-terminally truncated isoforms (\( \Delta N \)-p63). Both TA and \( \Delta N \) transcripts undergo alternative splicing to form \( \alpha \), \( \beta \), and \( \gamma \) variants [1].

The TA domain of p63 has a single p300-binding site, whose sequences are conserved among p53 family proteins, to transactivate target genes [7]. In contrast, \( \Delta N \)-p63 proteins lack the entire TA domain and instead have \( \Delta N \)-specific sequences of only 14 amino acid residues. Based on the structural aspect and inhibition of p53 and TA-p63, \( \Delta N \)-p63 proteins were originally defined as dominant-negative type suppressors against p53 family [1].

Well-differentiated squamous cell carcinomas of head-and-neck, as well as carcinomas of lung, urothelia, breast, skin etc., exhibit high-level expression of p63 [3,8]. Importantly, the loss of p63...
expression was associated with malignant progression [9–12]. As the ΔN-p63-α isoform is the most abundant p63 protein in these carcinomas and keratinocyte stem cells [1,13–15], ΔNp63α is hereafter referred to as p63 unless otherwise specified.

A genome-wide search for p63-binding sites resulted in the identification of direct p63-binding sequences corresponding to the p53-binding motif as well as the motifs of transcription factors essential for tissue development [16]. Unlike the original characterization, p63

---

| p63 | β-cat | Lane | 0 | 30 | 50 | 70 |
|-----|-------|------|---|----|----|----|
| p63 | β-cat | Lane | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |

≥ twofold decrease by 6 ng/well of p63/mutants

No significant effect observed

≥ twofold increase by 6 ng/well of p63/mutants
lacking the TA domain appeared to upregulate transcription in some cases [16,17]. For instance, p63 enhances PERP expression, where the molecular mechanism remains unidentified [18], p63 directly activates HSP70 by interacting with nuclear transcription factor Y (NF-Y) [19], although cell cycle G2/M promoters were repressed by the p63-(NF-Y) interaction [20].

Others and we reported that p63 binds to HMG domain of lymphoid enhancer factor/T-cell factor (TLE/TCF) proteins to antagonize β-catenin [21,22]. However, some results were not absolutely consistent with this conclusion. In a p63-expressing squamous cell carcinoma line, Wnt/β-catenin target genes such as MMP7 and AXIN2 were indeed upregulated by p63 knockdown, whereas expression of SNAI2, CCND2 and MYC decreased as p63 diminished. When analyzed with pGL3-OT, a widely used Wnt/β-catenin-responsive reporter plasmid, p63 suppressed β-catenin-dependent transcription in Saos-2 and Huh7. In contrast, a β-catenin-enhancing effect of p63 was observed in HEK293 cells with the same plasmid [21–23].

We considered these disputable results as manifestation of as yet unknown mechanisms with p63. This study explored molecular interactions underlying the positive and negative regulation of Wnt/β-catenin-dependent gene expression by p63.

Materials and Methods

Plasmids

The p63-coding sequences (NM_001114980, variant-4 of TP63) from the codon-optimized clone (Origene Technologies, RC225987) were recloned into pCMV6-Ac-HA vector to express p63 with C-terminal hemagglutinin (HA) tag (pCMV6-p63HA). The p300 expression vector, pCMVb-p300, was a gift from William Sellers, Dana Farber Cancer Institute (Addgene plasmid # 10717). Plasmids for the expression of nuclear-targeted S33Y-β-catenin and Myc-tagged-TCF4 as well as pGL3-OT, pGL3-OF, and pGL3-OT-del-p53FM were previously described [22]. Deletion mutants, p63-dN3 and p63-dD1, were generated from pCMV6-p63HA using the PrimeSTAR Mutagenesis Basal Kit (Clontech-Takara Bio, R046A). PCR primers used were as follows: p63-dN3 (p63-dN3-F, 5′-TGAAAA ACTCCACCTTTG ATGTCTT-3′; p63-dN3-R, 5′-AAGTGGAGTGGTTCCAGG TACA ACAT-3′) and p63-dD1 (p63-dD1-F, 5′-CTGAGCA CAAGCAGCAAGTTTCGGACAC-3′; p63-dD1-R 5′-TTGCTGCTTGTGCTCAGCTTTTTGTAG-3′). pCMV6-p63HA was digested with MunI and NotI to remove the C-terminal domain sequences and circularized with a linker (dC2HA-FOR, 5′-AATTACGCGTACGC-3′; dC2HA-REV, 5′-GGCCGGCTACGCCTG-3′) to form p63-dC2. As the codon-optimized pCMV6-Entry clone caused an eight-fold increase in p63 protein synthesis as compared with the previously used pRc/CMV clones [22], we proportionally decreased the amount of p63-expression vectors. Codon-optimized adenosine type-5 Flag (KDD)-tagged E1A (Accession number AP_000197) and E1b-55 K (AP_000199) expression vectors were from Origene Technologies (VC100110 and VC100112).

Luc Reporter Assay

Cells were seeded (8 × 10^4 cells/well) in 24-well plates 24 h before transfection. In addition to the luc vector (25 ng/well) and Myc-TCF4 expression vector (25 ng/well), those of nuclear-targeted S33Y-β-catenin (0, 30, 50, and 70 ng/well) and p63 (0, 3, and 6 ng/well) were introduced. A total of 130 ng of DNA was transfected into each well with Effectene (Promega). Cells were lysed with Glo-lysis buffer (Promega) at 48 h. Luc enzyme assay was carried out as previously described [22]. All transfection experiments were performed in triplicate, and results shown as mean ± S.D. Each transfection was repeated at least two times with similar results.

Immunoprecipitation and Western Blotting

Saos-2 cells were seeded (10^6 cells/well) in 6-cm plates 24 h prior to transfection. DNA (2 μg) was transfected in each plate with Turbofectin 8.0 (Origene). At 48 h, plates were chilled on ice, washed, and lysed with IP Lysis Buffer (Thermo Scientific, 87,787) supplemented with protease inhibitor cocktail (Sigma-Aldrich, S8820). After centrifugation, cell lysates were incubated with agarose conjugates with anti-HA (MBL, 561–8, rabbit IgG), anti-Myc (Abcam, Ab1253, goat IgG), or anti-p300 (Santa Cruz, sc-48,343, mouse IgG) for 2 h at 4 °C. Protein complexes were washed four times, and dissociated in SDS-PAGE sample buffer. We used 7.5% polyacrylamide gel (Mini-PROTEAN TGX, Bio-Rad) for SDS-PAGE. Anti-Myc (MBL, 562), anti-p63 (Abcam, Ab735), anti-p300 (Santa Cruz, sc-585), anti-NFYC (Santa Cruz, sc-390,861), anti-Flag (Sigma, F3165, M2), anti-E1A (Santa Cruz, sc-58,658) and anti-HDAC1 (Abcam, ab19845) antibodies were used for western blotting. Alkaline phosphatase-conjugated secondary antibodies (Cell Signaling Technology, #7056S and #7054S) were used in combination with Immune-Star AP Substrate (Bio-Rad, 1,705,018).

Cell Lines

Saos-2 cells were obtained from RIKEN BRC Cell Bank (RCB0428), and cultured in RPMI1640 medium (substituting McCoy’s 5A) supplemented with 10% fetal bovine serum. We also used FaDu (ATCC HTB-43) and A431 (ATCC CRL-1555) from American Type Culture Collection, and HSC-1 from JCRB (JCRB1015).

p63 Knockdown

p63 RNA-silencing was carried out by transfection of siRNA targeting p63 (p63i) and control siRNA (Ci) with siLentFect (Bio-Rad) as described [14,22].

Results

Positive and Negative Control of β-Catenin by p63

Luc reporter expression assay was performed in p53-null, p63-untransfected Saos-2 cells. To focus on the nuclear events, we used the constitutively active form of β-catenin (S33Y β-catenin) in

Figure 1. Suppression and coactivation of β-catenin by p63. Luc reporter assay was performed with pGL3-OT (A), del-p53FM-OT (B), and pGL3-OF (C). Expression vector of nuclear-targeted S33Y-β-catenin was used at indicated amounts (ng/well). Increasing amounts of p63 expression plasmids (0, 3, and 6 ng/well) were also introduced (dark right triangle). Dark columns indicate that luc activity decreased to one-half or less by p63/mutants (≥ twofold decrease by 6 ng/well of p63/mutants), while white columns indicate an increase of twofold or more by p63/mutants (≥ twofold increase by 6 ng/well). Gray columns show that the alteration was not significant. Domain structures of p63 and mutants are outlined (D). The N-terminal ΔN-specific region (blue), proline-rich region (peach), DNA-binding domain (right green), oligomerization domain (yellow), and C-terminal α-domain (red) are depicted. Protein interactions detected in Figure 2 are also summarized.
In addition to the wild-type (WT) p63, the following deletion mutants were examined: p63-dC2, p63-dN3, and p63-dD1 (Figure 1D). p63-dC2 had a deletion of the entire α-domain at the C-terminus (residues 356–586). p63-dN3 lacked the N-terminal structure (residues 7–59), while p63-dD1 lacked a large part of the DNA-binding domain (143–266) but retained the presumed
nuclear localization signal and oligomerization domain as well as the α-domain. Different amounts of p63 and mutants (0, 3, and 6 ng for one well with 8 x 10^4 cells) (Figure 1A, dark right triangle) were transfected in combination with S33Y β-catenin expression plasmid (0, 30, 50, and 70 ng/well). Constant amounts of the Myc-TCF4 expression vector and pGL3-OT luc plasmid having three copies of Wnt/β-catenin response element (WRE) and a p53 family protein binding motif (p53FM) [22] (Figure 1A) were contained in the transfection mixture.

When S33Y β-catenin was increased from 30 to 50 and 70 ng/well, in the absence of p63, we observed no further increase in luc expression (Figure 1A, top panel, lanes 4, 7, and 10, respectively), implying that β-catenin-dependent transcription reached the maximum level by saturation of myc-TCF4 with S33Y β-catenin. Under the assay conditions, we examined how p63 influenced β-catenin-driven transcription. Consistent with our previously described results with WT β-catenin [22], p63 exerted an inhibitory effect against S33Y β-catenin at ≤30 ng/well (Figure 1A, top, compare lane 4 with lanes 5 and 6). Interestingly, p63 failed to suppress S33Y β-catenin at 50 ng/well (compare lane 7 with lanes 8 and 9), but enhanced S33Y β-catenin at 70 ng/well (lanes 10–12). p63 was unable to activate luc expression without β-catenin transfection (lanes 1–3).

p63-dC2 retained the S33Y β-catenin (30 ng) suppressive activity (Figure 1A, second panel, lanes 4–6), which was less prominent with S33Y β-catenin at 50 ng/well. In contrast to WT p63, dC2 mutant failed to enhance S33Y β-catenin at 70 ng/well. Thus, the α domain seemed responsible for the β-catenin-enhancing function of WT p63.

p63-dN3 showed both β-catenin-suppressing (Figure 1A, the third panel, lanes 4–6) and coactivating (lane 10–12) effects as p63 did, although a minor alteration in kinetics was observed: This mutant suppressed not only 30 ng/well but also 50 ng/well of S33Y β-catenin (lanes 7–9). Thus, the N-terminal structure of p63 was unnecessary for suppression and coactivation of β-catenin. p63-dD1 neither down-regulated nor up-regulated S33Y β-catenin at 30–70 ng/well (Figure 1A, bottom). The DNA binding domain may contribute to the control of β-catenin in both directions.

**p53FM Facilitates Coactivation of β-Catenin by p63**

We performed luc assays with the pGL3-OT-del-p53FM plasmid (here referred to as Del-p53FM-OT), in which the p53 family protein-binding motif (p53FM) was deleted (Figure 1B) [22]. As observed with pGL3-OT (Figure 1A, top), S33Y β-catenin at 30 ng/well hit the plateau of transcriptional activation, allowing no further activation with 50 or 70 ng/well of S33Y β-catenin (Figure 1B, top, lanes 4, 7, and 10, without p63). WT p63 suppressed S33Y β-catenin at 30 ng/well (Figure 1B, top, lanes 4–6) but failed to decrease or increase luc expression at 50 ng/well of S33Y β-catenin (lanes 7–9). Thus, p63 did not enhance 70 ng/well of S33Y β-catenin (lanes 10–12) in the absence of p53FM.

p63-dC2 and p63-dN3 also suppressed the lower amount of S33Y β-catenin when tested with del-p53FM-OT (Figure 1B, second and third panels, lanes 4–6). Neither of the p63 mutants enhanced luc expression induced by S33Y β-catenin at 70 ng/well (lanes 10–12). As observed with pGL3-OT (Figure 1A, bottom), p63-dD1 showed neither positive nor negative influence on luc expression by 0–70 ng/well of S33Y β-catenin (Figure 1B, bottom, lanes 1–12). Thus, the p53FM sequence in pGL3-OT was found to facilitate the p63- and p63-dN3-mediated coactivation of S33Y β-catenin when luc expression reached plateau.

We also used pGL3-OF, a widely used control plasmid, wherein each WRE was destroyed by two nucleotide mutations preserving the p53FM site (Figure 1C). p63 had no inhibitory or stimulatory effect on luc expression in the presence (50 and 70 ng/well, lanes 4–9) or absence (lanes 1–3) of S33Y β-catenin. Thus, p63 (in the isomform of ΔNp63α) was evidently unable to transactivate p53FM. These experiments with del-p53FM-OT and pGL3-OF indicated that p53FM facilitated β-catenin coactivation by p63. However, this coactivation required higher amounts of S33Y β-catenin and functional WREs, and, therefore, was distinguished from transactivation of the target site by TA-p63.

**p63 Domain-Specific Interactions With Proteins**

To understand the mechanisms underlying the positive and negative effects of p63 on β-catenin-dependent transcription, we analyzed protein–protein interactions. HA-tagged p63 and the deletion mutants (p63-dC2, p63-dN3, and p63-dD1) were transfected into Saos-2 cells, followed by immunoprecipitation with an anti-HA antibody (Figure 2A). Ectopically expressed WT and mutant p63 often appeared with lower molecular weight proteins, indicating intracellular degradation. Particularly, p63-dN3 was observed as a doublet, of which the upper band corresponded to the full-length protein. The dN3 deletion may have exposed an N-terminal peptide sensitive to cellular enzymes [24].

While p63 and its mutant proteins were efficiently precipitated, the abundantly expressed C subunit of NF-Y (NF-YC), was absent in p63 precipitates. Unlike the observation of cell cycle G2/M gene repression by p63 [20], the p63-(NF-YC) interaction may be irrelevant to this experimental system.

After transfection of Myc-TCF4 in combination with p63 or its mutants, proteins were precipitated with an anti-Myc antibody (Figure 2B). Consistent with our previous results, p63 was coprecipitated with Myc-TCF4 [21,22]. p63-dC2 and p63-dN3 were also associated with Myc-TCF4 with varied efficiencies. In
contrast, p63-dD1 was undetectable in the Myc-TCF precipitate. These observations were supported by the result that the amino acids 81–290 of p63 are essential for the interaction with the HMG domain of LEF/TCF [21]. Considering that p63 was able to enhance β-catenin (Figure 1A), we hypothesized involvement of p300 (EP300), a transcriptional coactivator/adaptor protein with histone acetyltransferase activity [25]. In fact, p300 is known as a coactivator of β-catenin [26]. After transfection

**A** pGL3-OT

Suppression of moderately induced β-catenin

β-catenin

p53FM

TCF4

WRE x 3

**B** Del-p53FM-OT

Suppression of moderately induced β-catenin

β-catenin

p53FM

TCF4

WRE x 3

**C** pGL3-OF

No suppression or activation by p63

p53FM

Mut x 3

**D** p63 (ΔNp63α)

ΔN domain (1-14)

Nuclear localization signal & oligomerization domain (280-329)

SAM (447-512)

TID (513-586)

Proline-rich flexible loop (39-80)

DNA binding domain (83-267)

Target DNA sequences

TCF4

p300

p53

TA domain

ΔN domain (1-14)

p300

ΔN domain (1-14)

p300

γ domain

p300

ΔN domain (1-14)

p300

ΔN domain (1-14)
of p300 in combination with p63, p63-dC2, p63-dN3, or p63-dD1, proteins were precipitated with an anti-p300 antibody (Figure 2C). As the result, p63 appeared as a dense band on the western blot, suggesting a strong interaction between p63 and p300. Both p63-dN3 and p63-dD1 were also coprecipitated with p300, but p63-dC2 was not. Thus, we found that p300 is a partner of p63, for which the C-terminal domain of p63 is essential. The protein interactions observed in Figure 2, B and C are schematically shown in Figure 1D.

To test whether p63 impairs the interaction between β-catenin and p300, Myc-tagged β-catenin and p300 were transfected with or without p63. The anti-Myc antibody precipitated p300 with Myc-β-catenin, and the interaction was unaffected by p63 (Figure 2D). Thus, p63 neither inhibited nor facilitated the β-catenin-p300 association. Furthermore, p63 was absent in the immune complex, indicating that the tripartite complex of “β-catenin-p300-p63” was improbable. The p63-p300 complex (Figure 2C) may exist apart from the β-catenin-p300 complex.

**Hypothetical Model of the Positive and Negative Regulation of β-Catenin by p63**

Based on the results of reporter assays (Figure 1) and immunoprecipitation (Figure 2), we hypothesized mechanisms underlying the suppression and coactivation of β-catenin by p63 (Figure 3). p63 antagonizes β-catenin by binding to LEF/TCF (Figure 3A, left) [21,22]. The HMG-binding region of p63 (residues 81–290) overlaps with the DNA-binding domain (83–267) (Figure 1D). When the TCF4 molecules are saturated with increased amounts of β-catenin to achieve the maximum luc expression, p63 seems to act with p53FM to coactivate β-catenin (Figure 3A, right). Because p63-dC2 was able to suppress but not coactivate β-catenin with pGL3-OT (Figure 1A), the interaction of the C-terminus with p300 may be essential for the coactivator function of p63.

In the absence of p53FM in the enhancer region, p63 inhibited lower concentrations of β-catenin (Figures 1B, 3B, left). During the maximum transcriptional activation by β-catenin, however, p63 neither inhibits nor enhances β-catenin (Figure 3B, right). p63 may be “competed-out” by β-catenin occupying TCF4, but lack any alternative element to interact. In addition, p63, in the form of ΔNp63α, does not directly transactivate p53FM in the absence of WRE sequences (Figures 1C, 3C).

**Analyses of Endogenous p63 in Squamous Cell Carcinomas**

We next assessed relevance of the p63-p300 interaction and the model of β-catenin coactivation in p63-expressing squamous cell carcinoma line, FaDu [14]. Since p300 (EP300) was initially identified as an adenovirus E1A-binding protein [27], we transfected Flag-tagged E1A (Flag-E1A) (Figure 4A, left). In addition, Flag-E1B-55 K was used as the control protein without an affinity to p300 [28]. When precipitated with an anti-Flag antibody, Flag-E1A was co-precipitated with endogenous p300. In contrast, the Flag-E1B-55 K precipitate did not contain p300. Neither of the precipitates contained endogenous p63. We next carried out immunoprecipitation with an anti-p300 antibody after Flag-E1A transfection (Figure 4A, right). Endogenous p63 was coprecipitated with p300, as efficiently as Flag-E1A was. p63 may be one of the numerous transcription factors interacting with p300 [25]. In contrast, HDAC1 (histone deacetylase 1) was little detected in the anti-p300 precipitate. Thus, our experimental system revealed specific p300-protein interactions. Furthermore, endogenous p63-p300 complex formation occurred physiologically in FaDu cells.

As shown previously, β-catenin-responsive genes, MMP7 (matrix metalloproteinase-7), and CCND2 (cyclin d2), were sensitively responded to p63-knockdown, in which the former was upregulated by p63-knockdown, while the latter was down-regulated [22]. As analyzed for gene expression with a whole genome microarray, p63-knockdown efficiencies (fold change in p63) differed depending on cell lines, FaDu, HSC-1, and A431, probably reflecting the siRNA transfection efficiencies (Figure 4B). Nevertheless, we constantly observed that MMP7 expression was increased by p63 silencing, while CCND2 expression declined as p63 diminished.

To assess the possibility of β-catenin coactivation by p63 (Figure 3A, right) with the chromosomal DNA sequences, we tested the regulatory sequences, MMP7-WRE1 (found in Enhancer ID GH11J102530, Genome Locator), and CCND2-WREb (GH11J004268), by the reporter assay (Figure 4C). When activated by WT β-catenin approximately 4-fold, these enhancers were evidently repressed by p63 as reported [22]. With S33Y β-catenin (30 ng/well) causing 7–9-fold activation, p63 was still able to repress these enhancers (Figure 4C, a, b, lanes 4–6). When activated 10-fold by S33Y β-catenin (50–70 ng/well, a, lanes 7–12), p63 neither enhanced nor repressed MMP7-WRE1-rep. In contrast, upregulation of CCND2-WREb-rep by p63 became detectable under the full activation by S33Y β-catenin (Figure 4C, b, lanes 7–12).

**Discussion**

We observed that p63 influences β-catenin-driven transcription in various modes, as examined with pGL3-OT, its truncated forms, and chromosomal MMP7 and CCND2 enhancer sequences. p63 can act in the β-catenin-suppressing and coactivating modes, depending on the enhancer structure and the magnitudes of β-catenin activation. We also analyzed interactions between p63 and β-catenin-related essential nuclear proteins in p63-transfected and endogenously expressing carcinoma cells. Our results newly showed that p300 is a partner of p63. The C-terminal domain of p63 interacts with p300, which is correlated to the β-catenin coactivating function of p63.
Genomic WREs may respond to p63 in various manners depending on the regulatory sequences, accessibility to β-catenin and other factors in the local chromatin microenvironment. At the CCND2-WREb enhancer with p53FM-like motifs, p63 may possibly coactivate β-catenin sufficiently induced in squamous cell carcinomas. In contrast, the MMP7-WRE1 enhancer without p53FM may be suppressed by p63. The so-called ‘exceptional’ result detected in HEK293 cells that p63 enhanced β-catenin in p53FM-dependent manner [22] may correspond to the coactivation mode (Figure 1A, top, lanes 10–12; Figure 3A, right). HEK293 cells

| Transfection     | Lys | IP/Flag |
|------------------|-----|---------|
| Flag-E1A         | +   | -       |
| Flag-E1B-55K     | -   | +       |
| Vec              | -   | +       |

**FaDu cells**

| Transfection     | Lys | IP/Flag |
|------------------|-----|---------|
| Flag-E1A         | +   | +       |

A

![Image of Western Blot](image1)

B

**CCND2 and MMP7 expression altered by p63 knockdown**

![Graph of p63 (fold change) vs. CCND2 and MMP7 expression](image2)

C

| MMP7-WRE1-rep-Luc | Activation (fold) |
|-------------------|-------------------|
| p63               | 0 30 50 70        |
| S33Yβ-catenin     | 0 30 50 70        |
| Lane              | 1 2 3 4 5 6 7 8 9 10 11 12 |

| CCND2-WREb-rep-luc | Activation (fold) |
|--------------------|-------------------|
| p63                | 0 30 50 70        |
| S33Yβ-catenin      | 0 30 50 70        |
| Lane               | 1 2 3 4 5 6 7 8 9 10 11 12 |
The HMG domain of TCF/LEF binds to the target DNA sequences, or WRE. In addition to p63, other factors of distinct signaling pathways are known to physically interact with HMG. For instance, Smad3 binds to HMG of LEF1/TCF to synergistically activates Xwnt gene with β-catenin, wherein Smad-binding and TCF/LEF-binding elements are tandemly aligned [30]. The HMG-binding region of p63 (residues 81–290) determined by Dreweles et al. [21] overlaps with the DNA-binding domain (83–267), which contains an ‘aggregation-prone peptide’, PILTIVTLE (226–233), identified in p53 [31]. The lack of TCF4-binding activity in p63-dD1 may imply contribution of the hydrophobic peptide to the p63-TCF4 interaction.

The coactivation mode of p63 (ΔNp63α) was distinguished from the well-described transactivation mode of p53 and TA-p63, because the coactivation required stronger induction of β-catenin and functional WREs to which TCF/LEF proteins bind. The TA domain of TA-p63 isoforms interacts with p300 with a stretch conserved among p53 family proteins. (Figure 3D) for transcriptional activation [7]. In the case of TAP63α, interestingly, the ‘transcription inhibitory’ domain (TID) at the extremely C-terminus of the α-domain directly binds to the TA domain to block the transactivating function [32–34]. In the scheme, The TID protects the TA domain from p300-binding in the inactive dimer complex, but does not seem to compete against the TA domain for p300 either in the dimer or in the active tetramer. In the central part of α domain lies a sterile alpha motif (SAM) with which various protein interactions are expected [35]. Although the possibility of TID-p300 interaction is not ruled out, the SAM domain may be able to serve as the p300-binding site in the ΔNp63α–p300 complex.

The TID was also found to interact with HDAC1 and HDAC2 histone deacetylases to suppress target genes of p53, such as p21, 14–3–3γ, and p16/INK4a in epidermal progenitor cells, and PUMA in squamous cell carcinomas [36,37]. As p63 can regulate transcription both positively and negatively depending on the enhancers [16,22], these results are not necessarily opposed to our finding. In addition, the negative regulation may result from the dominant negative effect, interaction with cofactors, or cooperation with HDACs.

p300 is regarded as an epigenetic factor that accelerates transcription by relaxing the chromatin structure and assembling various enhancer-binding proteins and the initiation complex [25]. A recent study explained that histone H3 acetylation at Lys 27 (H3K27ac) by p300 or its close relative CBP is essential for enhancer activation [38]. A comprehensive epigenetic study suggested that p63 binding sites at active enhancers with H3K27ac predict p63 target genes in human epidermal differentiation [39]. Furthermore, inherited p63 mutations that manifest epidermal defects poorly bind to the enhancers involved in keratinocyte differentiation, where H3K27ac signal is also decreased [40]. Thus, our finding may offer a molecular basis for the proposed ‘bookmarking’ function of p63 [41].

Conclusion

We newly detected complex formation between the C-terminal α domain of p63 and p300, proposing a model of β-catenin coactivation by p63. In addition to the dominant-negative type suppressor function against p53 family transactivators, p63 (in the form of ΔNp63α) may be able to play as a positive regulator of gene expression through the functions of p300.

Acknowledgements

This work was supported by Grant-in-Aid for Scientific Research (C) (JSPS 15K11090) to SK.

References

[1] Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, and McKeon F (1998). p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2, 305–316.
[2] Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, and Obinata M, et al (1998). Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4, 839–843.
[3] Hibi K, Trink B, Pattrajjan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, and Sidransky D (2000). AIL is an oncogene amplified in squamous cell carcinoma. PNAS 97, 5462–5467.
[4] Crem CP and McKeon FD (2010). p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 5, 349–371.
[5] Yang A, Schweiter R, Sun D, Kaghad M, Walker N, Bronson RT, Talin C, Sharpe A, Caput D, and Crem C, et al (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714–718.
[6] Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, and Bradley A (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708–713.
[7] Krauskopf K, Gebel J, Kazemi S, Tuippi M, Lohr F, Schafer B, Koch J, Guntert P, Dotsch V, and Kehrel B (2018). Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain. Structure 26, 1091–1100 [e1094].
[8] Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, and Carbone DP, et al (2003). Significance of p63 Amplification and Overexpression in Lung Cancer Development and Prognosis. Cancer Res 63, 7113–7121.
[9] Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, Ince TA, McKeon FD, and Cordon-Cardo C (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161, 1199–1206.
[10] Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E, Trink B, and Kihara K (2009). Loss of ΔNp63alpha promotes invasion of urothelial
Higashikawa K, Yoneda S, Tobiume K, Taki M, Shigeishi H, and Kamata N (2007). Snail-Induced Down-Regulation of [Delta]Np63[alpha] Acquires Invasive Phenotype of Human Squamous Cell Carcinoma. Cancer Res 67, 9207–9213.

Nylander K, Coates PJ, and Hall PA (2000). Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer 87, 368–372.

Kurata S, Okuyama T, Osada M, Watanabe T, Tomimori Y, Sato S, Iwai A, Nylander K, Coates PJ, and Hall PA (2000). Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer 87, 368–372.

Fukunishi N, Katoh I, Tomimori Y, Tsukinoki K, Hata R, Nakao A, Ikawa Y, Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, and Struhl K (2006). Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 24, 593–602.

Okuyama T, Kurata S, Tomimori Y, Fukunishi N, Sato S, Osada M, Tsukinoki K, Jin HF, Yamashita A, and Ito M, et al (2008). p63(TP63) elicits strong transcriptional regulation. J Biol Chem 283, 34502–34508.

Vo N and Goodman RH (2001). CREB-binding protein and p300 in carcinomas via N-cadherin/Src homology and collagen/extracellular matrix properties of a transcriptional adaptor. Genes Dev 8, 869–884.

Blackford AN and Grand RJ (2009). Adenovirus E1A 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol 83, 4000–4012.

Guiral TS and MacBeath G (2010). A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation. PLoS One 5(10):e100024.

Labbe E, Letamendia A, and Artisiano I (2000). Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci U S A 97, 8358–8363.

Ghosh S, Ghosh D, Ranganathan S, Anoop A, P SK, Jha NN, Padinhateeri R, and Maji SK (2014). Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53. Biochemistry 53, 5995–6010.

Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, Darimont BD, Dujif PH, Van Bokhoven H, and McKeon F, et al (2002). A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 22, 8601–8611.

Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Schafer B, Hannewald J, Luh LM, Drent FG, Ibrahim M, and Hoffmann J, et al (2011). DNA damage in oocytes induces a switch of the quality control factor TAp63alpha from dimer to tetramer. Cell 144, 566–576.

Kuhrolesser S, Osterburg C, Tupp M, Schafer B, Vosden KH, and Dotsch V (2016). Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family. Cell Death Differ 23, 1952–1960.

Thanos CD and Bowie JU (1999). p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci, 1708–1710.

LeBoeuf M, Terrell A, Trivedi S, Sinha S, Epstein JA, Olson EN, Morrissey EE, and Millar SE (2010). Hdac1 and Hdac2 act redundantly to control p63 and p53 functions in epidermal progenitor cells. Dev Cell 19, 807–818.

Ramsey MR, He L, Forster N, Ory B, and Ellisin LW (2011). Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res 71, 4373–4379.

Rainsier R, Kharanda S, Jin L, Jeng E, Chan E, Merchant M, Haverly PM, Bainer R, Cheung T, and Arnott D, et al (2018). Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Rep 24, 1722–1729.

Kouwenhoven EN, Otti M, Niehues H, van Heeringen SJ, Schalkwijk J, Stunnenberg HG, van Bokhoven H, and Zhou H (2015). Transcription factor p63 bookmarks and regulates dynamic enhancers during epidermal differentiation. EMBO Rep 16, 863–878.

Qu J, Tanis SEJ, Smits JPH, Kouwenhoven EN, Otti M, van den Bogaard EH, Logie C, Stunnenberg HG, van Bokhoven H, and Mulder KW, et al (2018). Mutant p63 Affects Epidermal Cell Identity through Rewiring the Enhancer Landscape. Cell Rep 25, 3490–3503 [e3494].

Soares E and Zhou H (2018). Master regulatory role of p63 in epidermal development and disease. Cell Mol Life Sci 75, 1179–1190.

Ghioni P, D’Alessandra Y, Mansueto G, Jaffrey E, Hay RT, La Mantia G, and Guerini I (2005). The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 4, 183–190.

Katoh I, Aisaki KI, Kurata SI, Ikawa S, and Ikawa Y (2000). p51A (TAp63alpha), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 19, 3126–3130.